Trial Profile

An Open-Label, Parallel-Controlled, Multi-Center Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of Purinostat Mesylate for Injection Combined With Pomalidomide Capsules and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Purinostat Mesylate Chengdu Zenitar Biomedical Technology (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors Chengdu Zenitar Biomedical Technology

02 Apr 2025 Treatments section is updated to remove 3 mg/m2 dose cohort, only 4, 6 and 8.4 mg/m2 cohorts are continued, with increased number of patients, since planned enrollment is now increased from 126 to 144.
02 Apr 2025 Planned number of patients changed from 126 to 144.
19 Mar 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com